# Ipca Laboratories Ltd (IPCALAB)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹1571
Day Change: -1.94%
52W High: ₹1654
52W Low: ₹1252.95
Market Cap: ₹40,739 Cr

## Valuation
P/E: 44.84
P/B: 4.95
EPS: ₹35.81
Book Value: ₹324.6
Dividend Yield: 0.13%

## Returns
1Y Return: 8.28%

## Profitability
ROE: 0%
ROCE: 20.08%
Debt/Equity: 0.14
Revenue Growth: 6.6%
Profit Growth: 23.6%
EBITDA Margin: 19.76%
Operating Margin: 17.8%

## About
Ipca Laboratories Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Ipca Laboratories Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Quarterly Report: Board Meeting Intimation for Standalone And Consolidated Financial Results For 4Th Quarter And Financial Year Ended 31St March 2026 And Dividend
- Announcement: Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- BSE Filing: Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

## Access
Current tier: anonymous
More history: Register free to see 13 more years.

## Data Freshness
Quote Updated: 2026-05-25T12:00:11.977Z
Price History Updated: 2026-05-25T05:29:17.468Z
Latest Price History Date: 2026-05-24
Technicals Updated: 2026-05-25T05:29:17.468Z
Quant Updated: 2026-05-25T05:29:17.468Z
Sentiment Updated: 2026-05-25T05:29:17.468Z
Financials Status: current
Financials Updated: 2026-05-19T01:15:13.764Z
Financials Last Attempt: 2026-05-19T01:15:13.764Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (FY25)
Revenue: ₹8854.6 Cr
Operating Profit: ₹1355.87 Cr (OPM 15.31%)
Net Profit: ₹737.68 Cr
Tax: ₹343.61 Cr

## Annual P&L History
FY25: Rev ₹8854.6Cr | PAT ₹737.68Cr | OPM 15.31%
FY24: Rev ₹7622.41Cr | PAT ₹547.35Cr | OPM 12.26%
FY23: Rev ₹6206.85Cr | PAT ₹471.32Cr | OPM 11.35%

## Balance Sheet (FY25)
Total Assets: ₹11760.55 Cr
Total Liabilities: ₹3372.28 Cr
Borrowings: ₹1362.74 Cr
Cash: ₹167.17 Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Premchand  Godha A.C. A., B. Com., CA, Executive Chairman
- Pranay Premchand Godha, CEO, MD & Executive Director
- Ajit Kumar Bhanwarlal Jain A.C.A., B.Sc., CFO, MD & Executive Director
- Prashant Premchand Godha, Executive Director
- Pawan  Kothari, Vice President of Operations

---
Source: rupiya.io/stocks/ipcalab
Disclaimer: For research and education only. Not investment advice.